Activates dendritic cell function and antigen presentation, promotes antibody responses, activates TLR9 signaling, enhances NK cell activity. Bridges innate and adaptive immunity.
Hepatitis B/C adjunct, chemotherapy immune support, sepsis, post-viral immune recovery, COVID-19 adjunct.
Organ transplant recipients (immune activation could trigger rejection). Active autoimmune diseases. Hypersensitivity to thymic peptides.
Approved in 35+ countries. Multiple RCTs in hepatitis B and C. Vaccine adjuvant and sepsis data. FDA Orphan Drug designation.
- 1.Multiple groups, Lancet/Hepatology/J Hepatol 1998-2010 — improved viral clearance in chronic hepatitis B and C. Led to approval in 35+ countries. n=1,000+, multiple RCTs
- 2.Vaccine adjuvant studies, Vaccine/Clin Infect Dis 2005-2022 — enhanced vaccine responses in immunocompromised and elderly populations
Not FDA-approved despite approval in 35+ countries. Cancer monotherapy generally disappointing. Optimal dosing for anti-aging applications not established.
Post-COVID immune recovery applications. Cancer immunotherapy combination research expanding. Longevity medicine interest growing.